Shanghai Pharmaceuticals Holding Co. Ltd. Class A

Shanghai Pharmaceuticals Holding Co. Ltd. Class A

6.87
USD
-0.39
(-5.41%)
1.14EPS
7.34P/E
8.30BMarket Cap
Apr 01Next Earn

Total Valuation

USD

As of September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. carries a market capitalization of 8.30B, placing it among publicly traded companies globally. Its enterprise value stands at 11.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.30B
Enterprise Value11.82B

Important Dates

Shanghai Pharmaceuticals Holdings Co., Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. has 1.29B shares outstanding.

Shares Outstanding1.29B

Valuation Ratios

As of September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. trades at a trailing price-to-earnings ratio of 7.34. The price-to-sales ratio is 0.13, and the price-to-book ratio stands at 0.70.

PE Ratio7.34
PS Ratio0.13
PB Ratio0.70
P/TBV Ratio0.96

Enterprise Valuation

As of September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. trades at an EV/EBITDA multiple of 8.63 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.63 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 11.82B versus a market cap of 8.30B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.27
EV / EBITDA8.63
EV / EBIT8.63

Financial Position

As of September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.59, indicating elevated leverage, while an interest coverage ratio of 6.33 demonstrates adequate ability to service its debt obligations.

Current Ratio1.35
Quick Ratio0.30
Debt / Equity54.59
Debt / EBITDA5.59
Interest Coverage6.33

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2026. The company generates approximately 876,415.70 in revenue per employee across its workforce of 49,608.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee876,415.70
Employee Count49,608.00

Taxes

USD

Over the twelve months ended September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. recorded 346.65M in income tax expense. That works out to an effective tax rate of 25.60, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.35B, leaving 770.21M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax346.65M
Effective Tax Rate25.60

Stock Price Statistics

USD

As of the close on November 16, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd.'s stock has declined approximately 17.26% over the past 52 weeks. The 50-day moving average sits at 7.55, while the 200-day moving average is 7.58.

52-Week Price Change-17.26%
50-Day Moving Average7.55
200-Day Moving Average7.58

Income Statement

USD

Over the twelve months ended September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. generated 43.48B in revenue and converted that into 770.21M in net income, yielding earnings per share of 1.14. EBITDA reached 1.37B, while operating income came in at 1.50B.

Revenue43.48B
Gross Profit4.69B
Operating Income1.50B
Pretax Income1.35B
Net Income770.21M
EBITDA1.37B
EBIT1.37B
Earnings Per Share (EPS)1.14

Balance Sheet

USD

As of September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. holds 6.30B in cash and equivalents against 7.65B in total debt, resulting in a net debt position of 2.34B. Total book value stands at 11.84B, with working capital of 7.27B providing operational flexibility.

Cash & Cash Equivalents6.30B
Total Debt7.65B
Net Debt2.34B
Equity (Book Value)11.84B
Book Value Per Share9.15
Working Capital7.27B

Cash Flow

USD

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-337.61M

Margins

Over the twelve months ended September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. posted a gross margin of 10.79, reflecting its pricing power and cost economics. The operating margin of 3.45 and net profit margin of 1.77 provide insight into operational efficiency.

Gross Margin10.79
Operating Margin3.45
Pretax Margin3.11
Profit Margin1.77
EBITDA Margin3.15

Dividends & Yields

USD

Over the twelve months ended September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. paid dividends of 0.57 per share. The dividend payout ratio of 40.55 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 18.41, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai Pharmaceuticals Holdings Co., Ltd. shareholders.

Dividend Per Share0.57
Payout Ratio40.55
Shareholder Yield18.41

Scores

As of September 30, 2026, Shanghai Pharmaceuticals Holdings Co., Ltd. has an Altman Z-Score of 2.24, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.24